QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.102798v1 318/2/555    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, M. K. Articles by Son, M. H. Search for Related Content PubMed PubMed Citation Articles by Kim, M. K. Articles by Son, M. H.

ENDOCRINE AND DIABETES

An Orally Active Cathepsin K Inhibitor, Furan-2-Carboxylic Acid, 1-{1-[4-Fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), Inhibits Osteoclast Activity in Vitro and Bone Loss in Ovariectomized Rats

Dong-A Research Laboratories (M.K.K., H.D.K., J.H.P., J.I.L., J.S.Y., W.Y.K., S.Y.S., H.J.K., S.H.K., M.H.S.), Dong-A Pharmaceutical Co., Ltd., Gyeonggi-do, Republic of Korea; Yuhan Research Institute (C.H.L., J.Y.S., M.H.B., Y.A.S., Y.H., T.D.H., W.C., H.C., B.N.A.), Yuhan Corporation, Gyeonggi-do, Republic of Korea; and Department of Radiology (S.O.Y.), Eulji University Hospital, Daejeon, Republic of Korea.

Human cathepsin K, a cysteine proteinase of the papain family, has been recognized as a potential drug target for the treatment of osteoporosis. The predominant expression of cathepsin K in osteoclasts has rendered the enzyme into a major target for the development of novel antiresorptive drugs. Now, we report the pharmacological properties of OST-4077 [furan-2-carboxylic acid (1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide] as a novel selective cathepsin K inhibitor. Human and rat cathepsin K were inhibited in vitro by OST-4077 with the IC₅₀ values of 11 and 427 nM, respectively. OST-4077 suppressed bone resorption induced by rabbit osteoclasts (IC₅₀, 37 nM) but did not affect bone mineralization or cellular alkaline phosphatase activity in MC3T3-E1 cells. Parathyroid hormone-induced bone resorption was inhibited in a dose-dependent manner in thyroparathyroidectomized rats gavaged with a single dose of OST-4077 (ED₅₀, 69 mg/kg). When given orally twice daily for 4 weeks to 3-month-old ovariectomized (OVX) rats, OST-4077 dose-dependently prevented bone loss, as monitored by bone densitometry, ash content, and urinary excretion of deoxypyridinoline. No change in serum osteocalcin in the OVX rats by OST-4077 suggested that bone formation might not be affected by the agent. In summary, OST-4077 selectively inhibited bone resorbing activities of osteoclasts and prevented bone loss induced by estrogen deficiency but did not affect bone formation. OST-4077, an orally active selective human cathepsin K inhibitor, may have the therapeutic potential for the treatment of diseases characterized by excessive bone loss including osteoporosis.

Address correspondence to: Dr. Moon-Ho Son, 47-5, Sanggal-Dong, Giheung-Gu, Yongin-Si, Gyeonggi-Do 446-905, Republic of Korea. E-mail: ssonmh{at}donga.co.kr

This article has been cited by other articles:

				L. S. Bellesini, M. M. Beloti, G. E. Crippa, K. F. Bombonato-Prado, C. M. Junta, M. M. Marques, G. A. Passos, and A. L. Rosa The Effect of TAK-778 on Gene Expression of Osteoblastic Cells Is Mediated Through Estrogen Receptor Experimental Biology and Medicine, February 1, 2009; 234(2): 190 - 199. [Abstract] [Full Text] [PDF]

				R. Samadfam, Q. Xia, and D. Goltzman Pretreatment with Anticatabolic Agents Blunts But Does Not Eliminate the Skeletal Anabolic Response to Parathyroid Hormone in Oophorectomized Mice Endocrinology, June 1, 2007; 148(6): 2778 - 2787. [Abstract] [Full Text] [PDF]